TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39055703
Drug: Two-drug regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two-drug regimen (2DR) - dolutegravir or darunavir/cobicistat + lamivudine
Study: 39055703
Drug: Three-drug regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug regimen (3DR) - integrase inhibitor-based
Study: 39056160
Drug: IGU monotherapy
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IGU monotherapy (25 mg twice daily)
Study: 39056160
Drug: IGU +
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IGU + MTX (10-15 mg weekly for MTX and 25 mg twice daily for IGU)
Study: 39056160
Drug: MTX monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX monotherapy (10-15 mg weekly)
Study: 39056160
Drug: IGU monotherapy
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IGU monotherapy
Study: 39056338
Drug: AZD3427 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3427 (5, 15, or 45 mg)
Study: 39056338
Drug: AZD3427 (subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD3427 (subcutaneous injection)
Study: 39056349
Drug: Aficamten (5-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aficamten (5-20 mg)
Study: 39057291
Drug: Second-line axitinib
Normalized name: Axitinib
DrugBank: Axitinib (DB06626)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Second-line axitinib treatment
Study: 39058022
Drug: Cipargamin (intravenous)
Normalized name: Cipargamin
DrugBank: Cipargamin (DB12306)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cipargamin (intravenous)
Study: 39058662
Drug: QPOP-guided chemotherapy
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: QPOP-guided chemotherapy
Study: 39058740
Drug: Botulinum neurotoxin
Normalized name: Botulinum neurotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botulinum neurotoxin A (BoNT-A) injection into calf muscles
Study: 39058740
Drug: 0.9% saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% saline injection into calf muscles (placebo)
Study: 39058951
Drug: Copanlisib (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Copanlisib (60 mg IV) plus immunochemotherapy (rituximab and bendamustine)
Study: 39058966
Drug: Brentuximab vedotin
Normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Brentuximab vedotin (BV) added to multidrug chemotherapy
Study: 39059184
Drug: CDK4/6 inhibitor
Normalized name: Cdk4/6 inhibitor shr6390
DrugBank: Dalpiciclib (DB17456)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CDK4/6 inhibitor (CDK4/6i) therapy
Study: 39059184
Drug: Letrozole (upfront
Approvals — FDA: no, EMA: no, PMDA: no
Description: Letrozole (upfront therapy)
Study: 39059373
Drug: Sildenafil cream,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil cream, 3.6%
Study: 39059389
Drug: Longitudinal cfEBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: Longitudinal cfEBV DNA tracking during neoadjuvant chemotherapy and radiotherapy
Study: 39059398
Drug: Foritinib (80,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foritinib (80, 120, 160, or 210 mg orally once daily over 21-day cycles in phase 2a; 160 mg in phase 2b)
Study: 39059398
Drug: Foritinib (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foritinib (160 mg orally once daily in phase 2b)
Study: 39059407
Drug: BIIB078 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB078 (5 mg, 10 mg, 20 mg, 35 mg, 60 mg, or 90 mg)
Study: 39059407
Drug: BIIB078 (any
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIIB078 (any dose)
Study: 39060022
Drug: TG6050 (oncolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: TG6050 (oncolytic vaccinia virus encoding hIL-12 and anti-CTLA-4 antibody)
Study: 39060370
Drug: AB002 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB002 1.5 µg/kg
Study: 39060370
Drug: AB002 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: AB002 3 µg/kg
Study: 39060374
Drug: CI-8993 (fully
Approvals — FDA: no, EMA: no, PMDA: no
Description: CI-8993 (fully human IgG1κ monoclonal antibody)
Study: 39060961
Drug: Consolidation doublet
Normalized name: BAG,LEG LARGE CONSOLIDATED #0932
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation doublet chemotherapy (mFOLFOX6 or CAPOX) after neoadjuvant long-course chemoradiation (LCRT)
Study: 39060961
Drug: Consolidation triplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Consolidation triplet chemotherapy (mFOLFIRINOX) after neoadjuvant long-course chemoradiation (LCRT)
Study: 39060961
Drug: Neoadjuvant long-course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant long-course chemoradiation (LCRT) followed by consolidation chemotherapy
Study: 39061093
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonist, liraglutide
Study: 39061599
Drug: Maternal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternal blood biomarker test for spontaneous preterm birth risk screening followed by preventive treatments for those screening positive.
Study: 39062003
Drug: STP1 (combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: STP1 (combination of ibudilast and bumetanide)
Study: 39065260
Drug: TAK-426 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-426 (10 µg)
Study: 39065260
Drug: TAK-426 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-426 (2 µg and 5 µg)
Study: 39066382
Drug: Priorix vaccine
Normalized name: PRIORIX vaccine 0.5 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priorix vaccine (GlaxoSmithKline Biologicals)
Study: 39066382
Drug: Both vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both vaccines (Priorix and M-M-RII)
Study: 39066557
Drug: Non-steroidal anti-inflammatory
Normalized name: Non-steroidal anti-inflammatory agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-steroidal anti-inflammatory drug use (Control)
Study: 39066638
Drug: Spironolactone 100
Normalized name: spironolactone 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone 100 mg/day for 16 weeks
Study: 39066638
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate 100 mg/day for 16 weeks
Study: 39066638
Drug: Doxycycline hyclate
Normalized name: Doxycycline Hyclate
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline hyclate 100 mg/day
Study: 39066746
Drug: Invisalign First
Normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invisalign First Phase I treatment (CAT group)
Study: 39066962
Drug: Tumor Necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor Necrosis Factor inhibitors (TNFi)
Study: 39067509
Drug: Azelastine HCl
Normalized name: azelastine HCl
DrugBank: Azelastine (DB00972)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Azelastine HCl 0.15% nasal spray (2 sprays per nostril)
Study: 39067618
Drug: RAS inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: RAS inhibitors prescribed at discharge
Study: 39067870
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of carvedilol and VBL (group C)
Study: 39067870
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (Combination)
Study: 39067873
Drug: Ipilimumab 1
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab 1 mg/kg intravenously every 6 weeks plus nivolumab 240 mg intravenously every 2 weeks until disease progression or other criteria met.
Study: 39067876
Drug: Join4Joy approach
Approvals — FDA: no, EMA: no, PMDA: no
Description: Join4Joy approach in physical activity programmes, consisting of twelve, 1-hour weekly sessions of structured, supervised, group-based physical activity.
Study: 39068435
Drug: Steroid injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid injection (n=26)
Study: 39068435
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (neurodynamic exercise, steroid injection, advice)
Study: 39068937
Drug: Active weekly
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active weekly fever screening plus monthly RDT testing and treatment (group 3)
Study: 39068937
Drug: Active weekly
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active weekly fever screening (group 2)
Study: 39068937
Drug: Active monthly
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active monthly RDT testing and treatment (group 3)
Study: 39068945
Drug: Site-specific therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Site-specific therapy guided by a 90-gene expression assay
Study: 39068945
Drug: Empirical chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empirical chemotherapy
Study: 39069087
Drug: Proton or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton or photon beam therapy
Study: 39069096
Drug: Two doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two doses of original wild-type BNT162b2
Study: 39069259
Drug: Daily phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily phosphate measurements
Study: 39069269
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg C15:0 daily for 12 weeks
Study: 39069599
Drug: Ultra-rapid aspart
Normalized name: aspartate
DrugBank: Potassium aspartate (DB15819)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-rapid aspart (insulin type)
Study: 39069599
Drug: Aspart (insulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspart (insulin type)
Study: 39069967
Drug: Gefapixant 180
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 180 mg
Study: 39070019
Drug: 5-min daily
Normalized name: lenvatinib
DrugBank: Lenvatinib (DB09078)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 5-min daily meditation practice
Study: 39070019
Drug: 15-min daily
Normalized name: ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 15-min daily meditation practice
Study: 39070044
Drug: Increased predicted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased predicted anti-spike immunoglobulin G titer
Study: 39070853
Drug: Rimegepant 75
Normalized name: rimegepant 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rimegepant 75 mg oral tablet
Study: 39071916
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg L and 2 mg Z softgel (Carotenoid Group)
Study: 39072039
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy initiation and duration
Study: 39072042
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) with dihydroartemisinin-piperaquine+single-low dose primaquine
Study: 39073577
Drug: SAR monotherapy
Normalized name: SAR-125844
DrugBank: SAR-125844 (DB15382)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAR monotherapy
Study: 39073796
Drug: Consult for
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Consult for Addiction Treatment and Care in Hospitals (CATCH) program
Study: 39073799
Drug: Cemiplimab 350
Normalized name: CEMIPLIMAB
DrugBank: Cemiplimab (DB14707)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cemiplimab 350 mg intravenous every 3 weeks for up to nine treatment cycles
Study: 39073799
Drug: Baseline scores
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline scores (before treatment)
Study: 39073823
Drug: Invitation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services.
Study: 39073823
Drug: Invitation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services among Black individuals.
Study: 39073823
Drug: Invitation to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invitation to enroll in a program that reduced cost sharing for maintenance inhalers to $0 or $10 and provided medication management services among White individuals.
Study: 39074931
Drug: Niraparib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niraparib (200 mg) and Etoposide (50 mg)
Study: 39075274
Drug: Difamilast 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difamilast 0.3% ointment applied twice daily
Study: 39075274
Drug: Difamilast 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difamilast 0.3% or 1% ointment applied based on existing symptoms
Study: 39075354
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no vasopressor administration)
Study: 39075506
Drug: Healthcare worker
Normalized name: TRICLOSAN .01 g in 10 mL TOPICAL LIQUID [Zep Professional Healthcare Worker]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthcare worker HTN and CVD care training plus long-term practice facilitation, electronic health record (EHR) documentation of key indicators and use of reminders, and use of treatment partners to provide social support.
Study: 39075587
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus vitamin C
Study: 39075925
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 300 U/mL (Gla-300)
Study: 39076099
Drug: Trastuzumab biosimilar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab biosimilar (AryoTrust) administered every 3 weeks for nine cycles
Study: 39076483
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of TCFA and minimal lumen area (MLA)
Study: 39076569
Drug: Remote ischemic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remote ischemic preconditioning (RIPC) applied on the left upper limb twice daily, starting three days before DCB implantation.
Study: 39076593
Drug: SHR-1905 (50,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR-1905 (50, 100, 200, 400, and 600 mg)
Study: 39078582
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream applied twice daily for up to 52 weeks
Study: 39078582
Drug: Ruxolitinib cream
Normalized name: ruxolitinib Topical Cream
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ruxolitinib cream
Study: 39079614
Drug: FBT+ER (Family-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBT+ER (Family-based treatment with emotion regulation)
Study: 39079614
Drug: FBT (Standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: FBT (Standard Family-based treatment)
Study: 39079894
Drug: Active Conventional
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Conventional Treatment (ACT)
Study: 39079894
Drug: Biological treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biological treatments (including certolizumab pegol and tocilizumab)
Study: 39079926
Drug: Integrated evidence-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated evidence-based physical therapy (I-EPT) with mindfulness-based interventions
Study: 39080181
Drug: Stapokibart 600
Normalized name: Stapokibart
DrugBank: Stapokibart (DB18990)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stapokibart 600 mg loading dose, then 300 mg every 2 weeks for 52 weeks
Study: 39080350
Drug: Dactinomycin and
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dactinomycin and Vincristine (AV) chemotherapy
Study: 39080350
Drug: Dactinomycin and
Normalized name: Dactinomycin
DrugBank: Dactinomycin (DB00970)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dactinomycin and Vincristine (AV) chemotherapy for bilateral stage I patients
Study: 39080380
Drug: Cuffs Collapsed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuffs Collapsed group (CC group, n=30)
Study: 39080698
Drug: Conservative management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative management (early mobilization under physiotherapy and analgesics)
Study: 39081141
Drug: Cognitive Orientation
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Orientation to Daily Occupational Performance (CO-OP) intervention, 12 sessions (2 sessions per week, 1 hour each, over 6 weeks)
Study: 39081682
Drug: No-added-sugar ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: No-added-sugar ice cream
Study: 39081682
Drug: Conventional ice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional ice cream
Study: 39081738
Drug: Lumasiran (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumasiran (36 months of treatment)
Study: 39081738
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 months of lumasiran treatment)
Study: 39355649
Drug: Lumasiran treatment
Normalized name: lumasiran
DrugBank: Lumasiran (DB15935)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Lumasiran treatment
Study: 39081763
Drug: Once weekly
Normalized name: Actonel 35 4-Week Once Weekly Dosepack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once weekly semaglutide
Study: 39082399
Drug: Sacubitril/valsartan (ARNI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sacubitril/valsartan (ARNI) therapy
Study: 39082406
Drug: Cardiovascular polypill
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardiovascular polypill (2 Polycaps taken orally once a day for 12 months, containing aspirin 100mg, simvastatin 20mg, hydrochlorothiazide 12.5mg, ramipril 5mg, and atenolol 50mg)
Study: 39082406
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (standard secondary prevention therapy)
Study: 39082803
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of meropenem
Study: 39082803
Drug: Intermittent infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermittent infusion (II) of meropenem
Study: 39083052
Drug: Pregnancy pilates-assisted
Normalized name: PREGNANCY TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnancy pilates-assisted birth preparation training (twice a week for 8 weeks)
Study: 39083052
Drug: Pregnancy pilates-assisted
Normalized name: PREGNANCY TEST
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregnancy pilates-assisted birth preparation training
Study: 39083105
Drug: Intraventricular radioimmunotherapy
Normalized name: cerliponase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraventricular radioimmunotherapy (RIT) with 925-1850 MBq (25-50 mCi) of radiolabeled antibody
Study: 39083099
Drug: VACStent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACStent treatment for anastomotic leak (AL) without stoma placement
Study: 39083099
Drug: VACStent treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: VACStent treatment for anastomotic leak (AL) after stoma placement
Study: 39083185
Drug: Narrow-diameter implants
Normalized name: narrowleaf marshelder pollen extract
DrugBank: Iva angustifolia pollen (DB10968)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Narrow-diameter implants with immediate provisionalization
Study: 39083288
Drug: Guselkumab 100
Normalized name: guselkumab 100 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 100 mg every 16 weeks
Study: 39083323
Drug: HER2-targeted PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER2-targeted PET/CT imaging before anti-HER2 therapy
Study: 39206189
Drug: AS01-adjuvanted vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AS01-adjuvanted vaccine
Study: 39083724
Drug: Sacituzumab govitecan
Normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Sacituzumab govitecan (SG) 10 mg/kg once on days 1 and 8 every 3 weeks
Study: 39083792
Drug: Telerehabilitation (TR)
Normalized name: hyoscyamine sulfate Extended Release Oral Tablet [Hyoscyamine TR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telerehabilitation (TR) administered via a web-based application, 1-hour sessions weekly for 4 weeks
Study: 39083792
Drug: Usual care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual care (UC) with home exercises provided on paper, 1-hour sessions weekly for 4 weeks
Study: 39083792
Drug: Clinic+TR group
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinic+TR group with in-person sessions and web-based platform for home exercises, 1-hour sessions weekly for 4 weeks
Study: 39083792
Drug: TR-only group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TR-only group with virtual sessions and web-based platform for home exercises, 1-hour sessions weekly for 4 weeks
Study: 39084177
Drug: Partial clinical
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial clinical remission (pCR) defined as stimulated C-peptide >300 pmol/l
Study: 39084177
Drug: Partial clinical
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial clinical remission (pCR) defined as insulin dose-adjusted HbA1c ≤9%
Study: 39084177
Drug: Partial clinical
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial clinical remission (pCR) defined as insulin dose <0.3 IU/kg/24 h and HbA1c ≤6.4% (46 mmol/mol)
Study: 39084177
Drug: Partial clinical
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Partial clinical remission (pCR) defined as insulin dose <0.5 IU/kg/24 h and HbA1c <7% (53 mmol/mol)